Clinical Trials Logo

Clinical Trial Summary

The incidence of colorectal cancer liver metastasis is high and the prognosis is poor. Improving the treatment effect of colorectal cancer liver metastasis is the key to improving the prognosis of colorectal cancer patients. Rigofenib is one of the standard third-line treatments for advanced colorectal cancer, but has limited efficacy. Immune checkpoint inhibitors (PD-L1 monoclonal antibody, PD-1 monoclonal antibody) have achieved good results in the treatment of various malignant tumors. In a mouse transplant tumor model of colorectal cancer, regorafenib combined with PD-1 monoclonal antibody treatment significantly improved the antitumor activity, but the efficacy rate in clinical studies was not very high, especially for liver metastases. Radiofrequency ablation (RFA) is one of the common methods for the treatment of liver metastases. RFA may improve the immune microenvironment and the efficacy of immunotherapy,and the purpose of this trial is to explore the efficacy and safety of rigofenib and terepliumab combined with RFA in patients with refractory colorectal cancer liver metastasis.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05485909
Study type Interventional
Source Sun Yat-sen University
Contact Zhiqiang Wang
Phone +8613825122020
Email [email protected]
Status Recruiting
Phase Phase 2
Start date July 25, 2022
Completion date June 30, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT04143516 - Tissue Analysis After Thermal Ablation for Colon Cancer Liver Metastases Leading to Immediate Retreatment Phase 2/Phase 3
Recruiting NCT04272931 - DRAGON 1- Training, Accreditation, Implementation and Safety Evaluation of Combined PVE/HVE N/A
Completed NCT02086656 - PERIOPERATIVE TREATMENT WITH COI-B (CAPECITABINE, OXALIPLATIN, IRINOTECAN AND BEVACIZUMAB) OF HIGH RISK OR BORDERLINE RESECTABLE COLORECTAL CANCER LIVER METASTASES Phase 2
Recruiting NCT03326791 - Aspirin in Colorectal Cancer Liver Metastases Phase 2/Phase 3